---
title: How Reimbursement Strategy Affects Your Regulatory Strategy
description: Reimbursement strategy regulatory strategy MedTech: plan both together. Evidence stack design, Article 61, classification and HTA, startup playbook.
authors: Tibor Zechmeister, Felix Lenhard
category: Funding, Business Models & Reimbursement
primary_keyword: reimbursement strategy regulatory strategy MedTech
canonical_url: https://zechmeister-solutions.com/en/blog/reimbursement-strategy-affects-regulatory-strategy
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# How Reimbursement Strategy Affects Your Regulatory Strategy

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **The biggest preventable mistake in MedTech is planning your regulatory strategy and your reimbursement strategy as two separate projects. They are one project with two audiences. Your intended purpose, your classification, and your clinical evidence plan will determine both whether you can sell the device and whether anyone will pay for it — and if you let one workstream finish before the other starts, you will pay to redo most of it.**

**By Tibor Zechmeister and Felix Lenhard.**

## TL;DR
- Regulatory evidence demonstrates safety, performance, and clinical benefit to a Notified Body under MDR Article 61.
- Reimbursement evidence demonstrates clinical and economic value to a payer or HTA body.
- The audiences are different, the acceptance criteria are different, but the underlying data is mostly the same — if you plan it that way.
- Intended purpose framing under MDR Article 2(12) simultaneously drives classification, clinical evidence, and the scope of HTA assessment.
- Classification decisions affect the size of your dossier and the type of comparator a payer will demand.
- Most startup failures in this area are not about regulatory or reimbursement quality in isolation; they are about misaligned framing between the two.

## Why this matters for MedTech founders

We see the same pattern almost every week. A startup spends 18 months and most of its seed round getting to CE mark. The clinical evaluation is compliant. The Notified Body is happy. The technical file is in order. The founders celebrate. Then they sit down with a payer for the first time — and the payer wants to see outcomes the clinical evaluation did not measure, against a comparator the clinical evaluation did not include, in a patient population the clinical evaluation did not stratify. The conversation ends politely. The founders go back to design another study, raise another round, and lose another year.

This is not a regulatory failure. The regulatory work was fine. It is a strategy failure — specifically, the failure to plan the evidence stack for two audiences from day one.

Regulatory reviewers and payers ask similar questions in very different language. The Notified Body asks: is this device safe, does it perform as claimed, does the benefit-risk ratio support the intended purpose? The payer asks: compared to what we already pay for, does this device deliver enough additional clinical and economic value to justify the price? Same underlying data, different framing, different comparators, different endpoints. If you design the clinical evaluation plan to answer only the Notified Body's questions, you are signing up for a second evidence programme later.

## What MDR actually says about clinical evidence

MDR Article 61 requires that the clinical evaluation be based on "sufficient clinical evidence, including, where applicable, relevant data as referred to in Article 61(3), to allow a qualified assessment of whether the device achieves the intended clinical benefit(s) and safety, when used as intended by the manufacturer." The clinical evaluation plan and the clinical evaluation report follow Annex XIV Part A. Post-market clinical follow-up under Annex XIV Part B is a continuous process, with a plan and a report, and is normally not optional.

Intended purpose is defined in Article 2(12): *"intended purpose means the use for which a device is intended according to the data supplied by the manufacturer on the label, in the instructions for use or in promotional or sales materials or statements and as specified by the manufacturer in the clinical evaluation"*.

That sentence is the pivot point of this entire post. The intended purpose you declare drives:
- Classification under Annex VIII (and therefore the whole conformity assessment route).
- The scope of the clinical evaluation — you only need to prove benefit for the intended purpose.
- The labelling and promotional claims you can make.
- The scope of any HTA assessment — payers assess the intended purpose, not what the device could theoretically do.
- The comparator a payer will select — it will be the standard of care for the exact indication you declared.

Narrow the intended purpose and the regulatory dossier shrinks — but so does the addressable market and the reimbursement scope. Widen it and the market grows — but so does the evidence burden and the comparator set. This is a strategic decision, not a drafting decision, and both the regulatory lead and the commercial lead need to be in the room when it is made.

## Where the silos go wrong

Three failure modes show up repeatedly.

The first is the narrow intended purpose trap. A startup declares a narrow intended purpose to shrink the Notified Body's scope of review and accelerate CE mark. It works — CE mark comes through quickly. But the reimbursement dossier now faces a market that is too small to justify a payer investment, or a patient population that does not align with the payer's coverage policy. The founders have to re-declare, update labelling, re-run clinical evaluation for the expanded indication, and resubmit.

The second is the wrong comparator. The clinical evaluation compares the device to "standard of care" defined generically — literature from multiple countries, multiple patient populations, different care pathways. The Notified Body accepts this because the state-of-the-art argument is defensible. The payer does not accept it because their assessment process requires a head-to-head comparison against the specific alternative they currently reimburse. The startup runs a second study.

The third is missing economic data. The clinical evaluation captures safety and clinical benefit but not cost, utilisation, length of stay, resource use, or health utility. The HTA body cannot complete its cost-effectiveness analysis and asks for more data. The startup runs a third study — or pays a health economics consultancy to model the data from scratch, which payers usually view with scepticism.

None of these failures is caused by poor MDR execution. They are all caused by treating the Notified Body and the payer as sequential rather than parallel audiences.

## A worked example: a Class IIb implantable sensor

A startup develops a Class IIb implantable continuous glucose monitor. The CE-mark pathway is demanding — Notified Body review, clinical evaluation under Article 61, clinical investigation under Chapter VI of the MDR and Annex XV, full QMS certification, PSUR under Article 86.

The founders sit down with the clinical lead and the commercial lead together at the start. Three decisions flow from that meeting.

Decision one: intended purpose. The draft intended purpose is "continuous measurement of interstitial glucose in adults with diabetes." The commercial team points out that the reimbursement conversation in Germany (G-BA) and France (HAS) will turn on Type 1 vs Type 2, and on whether the device is positioned as replacement for fingerstick or as adjunct. The team agrees to declare intended purpose covering both Type 1 and Type 2 adults, positioned as replacement for routine fingerstick measurements when clinically indicated, with a specified accuracy threshold. That scope supports the addressable market the investors were promised.

Decision two: the clinical investigation design. The Notified Body would accept a single-arm pivotal study against a reference standard (laboratory glucose measurement) to demonstrate accuracy and safety. The commercial team pushes for a two-arm design comparing the sensor to an already-reimbursed competitor device in a subset of patients, because that is the comparison the payer will demand. The extra arm adds cost and time but saves an entire second study later. The investigation is registered, ethics-approved, and run under EN ISO 14155:2020+A11:2024.

Decision three: the evidence capture plan. Alongside the primary regulatory endpoints (accuracy, adverse events), the investigation captures HbA1c, time-in-range, hypoglycaemia frequency, quality of life (EQ-5D), and healthcare resource use (fingerstick strips saved, unplanned clinical contacts, hospitalisation days). None of these are required by the Notified Body. All of them are required by the HTA body. Capturing them during the pivotal trial costs a fraction of what running a second economic study would cost later.

The CE mark comes through on schedule. The HTA submission goes to G-BA with the same trial as its primary evidence base — no second study needed. The price negotiation uses the EQ-5D and resource-use data directly. Time saved vs the sequential approach: roughly 18 months. Money saved: well into seven figures.

## The Subtract to Ship playbook for integrated planning

1. Draft the intended purpose with both regulatory and commercial leads in the room. If your draft has been written by the regulatory team alone, it will almost certainly need to be rewritten later — and rewriting it after CE mark is expensive.

2. Map classification against HTA scope before finalising the dossier. A classification that minimises Notified Body effort is not always the right answer if it also shrinks the reimbursement scope below a viable market.

3. Design the pivotal clinical investigation for two audiences. Add the comparator arm. Add the patient-reported outcome. Add the resource-use capture. The marginal cost of collecting extra endpoints inside an already-running trial is a fraction of the cost of running a second trial later.

4. Build one CER that serves both audiences. The body of the clinical evaluation report satisfies the Notified Body. A reimbursement annex — written against HTA criteria — draws from the same data to answer payer questions. Same evidence, two presentations.

5. Plan PMCF as the long-term evidence engine for both audiences. Continuous real-world data under Annex XIV Part B feeds reimbursement renewals as well as regulatory obligations.

6. Meet the HTA body early. Most major HTA bodies offer early scientific advice meetings. They will tell you what evidence they will want. Take that advice and feed it into the clinical investigation plan.

7. Make the regulatory lead and the commercial lead jointly accountable for the evidence strategy. If one reports up to product and the other reports up to the CEO, align them with a single evidence strategy document that both sign.

## Reality Check

1. Has your intended purpose been reviewed by both your regulatory lead and your commercial or reimbursement lead?
2. Does your clinical evaluation plan include the comparator that your target HTA body will demand?
3. Does your pivotal trial capture patient-reported outcomes and resource-use data, or only safety and clinical performance?
4. Have you requested scientific advice from at least one major European HTA body before finalising the trial protocol?
5. Is your classification decision driven purely by regulatory efficiency, or has it been tested against the reimbursement scope it creates?
6. Does your CER have a structure that can be repurposed into a reimbursement dossier, or will the reimbursement team start from scratch?
7. Is your PMCF plan designed to feed both MDR obligations and reimbursement renewal evidence?
8. Do regulatory and commercial report into a single evidence strategy, or two?

## Frequently Asked Questions

**Can I widen my intended purpose after CE mark to expand reimbursement scope?**
Yes, but it usually requires an updated clinical evaluation, possibly a significant-change notification to the Notified Body, and updated labelling. It is much cheaper to get the intended purpose right the first time.

**Will a Notified Body accept extra endpoints in my clinical investigation that are not needed for CE mark?**
Yes. Capturing additional data is not a problem for the Notified Body as long as the regulatory endpoints are properly specified and the trial is conducted under EN ISO 14155:2020+A11:2024.

**Do I need a separate health economics study for HTA?**
Often you can avoid a dedicated study by capturing the right variables in your pivotal clinical investigation — resource use, length of stay, quality of life utility scores. A separate study is only necessary if you need to model a long time horizon or a cost-effectiveness argument that the trial cannot directly support.

**How early should I engage with an HTA body?**
Before the pivotal trial protocol is locked. Most major European HTA bodies offer early scientific advice. The earlier you engage, the more likely your trial will generate data the HTA body actually wants.

**Can I use the same clinical evaluation report for CE mark and for reimbursement?**
The core document, yes. Most reimbursement processes require a country-specific dossier that wraps and re-presents the evidence in a prescribed format. The underlying evidence is the same.

**What if my Notified Body's timeline conflicts with the payer's timeline?**
It will. Plan the regulatory pathway and the reimbursement pathway as parallel workstreams with shared milestones. The critical path is usually the clinical investigation, and both audiences depend on it finishing on time.

## Related reading

- [MDR Article 61 clinical evidence requirements for startups](/blog/mdr-article-61-clinical-evidence-requirements-startups) — the regulatory core that sits under both audiences.
- [HTA submissions for medical devices](/blog/hta-submissions-medical-devices) — the payer-side evidence requirements in detail.
- [Intended purpose drives regulatory decisions](/blog/intended-purpose-drives-regulatory-decisions) — why the Article 2(12) framing matters so much.
- [Health insurance reimbursement in Europe](/blog/health-insurance-reimbursement-europe) — the broader reimbursement landscape.
- [Regulatory strategy supports business strategy](/blog/regulatory-strategy-supports-business-strategy) — how to keep the two aligned.

## Sources

1. Regulation (EU) 2017/745 on medical devices, consolidated text. Article 2(12), Article 61, Annex XIV Part A, Annex XIV Part B, Annex VIII.
2. MDCG 2020-5 (April 2020) — Clinical evaluation equivalence.
3. EN ISO 14155:2020+A11:2024 — Clinical investigation of medical devices for human subjects.

---

*This post is part of the [Funding, Business Models & Reimbursement](https://zechmeister-solutions.com/en/blog/category/funding-reimbursement) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*